mRNA COVID-19 vaccination caused a transient, subclinical NT-proBNP elevation within 14 days of the second dose, with 49% of healthy adults exceeding 1.5 times baseline without troponin changes.
Does mRNA COVID-19 vaccination cause elevation of cardiac biomarkers in healthy adults?
mRNA COVID-19 vaccination in healthy adults is associated with a transient, subclinical elevation in NT-proBNP without troponin elevation, suggesting mild, short-term myocardial stress rather than overt injury.
Absolute Event Rate: 0% vs 0%
Cardiovascular complications such as myocarditis and pericarditis have been reported following mRNA COVID-19 vaccination, particularly after the second dose. However, little is known about the cardiac biomarker response in otherwise healthy individuals after mRNA COVID-19 vaccination. This study aimed to investigate the dynamics of high-sensitivity cardiac troponins (hs-cTnI, hs-cTnT) and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) following mRNA COVID-19 vaccination. We analyzed serum samples collected at multiple time points between April and December 2021 from 83 healthy adult military personnel vaccinated with two doses of mRNA COVID-19 vaccines. Statistical analyses included mixed-effects ANOVA with Geisser-Greenhouse correction and logistic regression to assess the influence of covariates. NT-proBNP levels showed a significant but transient increase, particularly within 14 days after the second vaccine dose (geometric mean 36.2 pg/mL; p < 0.0001). Nearly 49% of participants exhibited a relative increase exceeding 1.5 times their individual baseline. No participant surpassed the 450 pg/mL threshold indicative of cardiovascular complications, and troponin levels remained unchanged across all assessed 14-day intervals. The observed NT-proBNP elevation was not significantly associated with any of the assessed covariates. However, non-significant trends were noted among men, individuals without prior COVID-19 infection or comorbidities, and those vaccinated with the mRNA-1273 (Moderna) vaccine. In healthy adults, mRNA COVID-19 vaccination was associated with a short-term, subclinical elevation in NT-proBNP, particularly after the second dose. While not indicative of overt cardiovascular injury, this biomarker response may reflect transient myocardial stress and warrants further research. • NT-proBNP peaked within 14 days after the second vaccine dose. • No change in hs-cTnI or hs-cTnT levels post vaccination. • Findings suggest short-term myocardial stress without clinical symptoms.
Dlouhý et al. (Sat,) reported a other. mRNA COVID-19 vaccination caused a transient, subclinical NT-proBNP elevation within 14 days of the second dose, with 49% of healthy adults exceeding 1.5 times baseline without troponin changes.